Global Stomach Cancer and Gastric Cancer Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026

  • receipt Report ID : 192659
  • calendar_today Published On: Mar, 2021
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Stomach Cancer and Gastric Cancer Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Stomach Cancer and Gastric Cancer Drugs size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Stomach Cancer and Gastric Cancer Drugs market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation

Stomach Cancer and Gastric Cancer Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Programmed Cell Death Protein 1 (PD-1) Inhibitors

Human Epidermal Growth Factor Receptor (HER2) Antagonists

Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists

Others

Market segment by Application, can be divided into

Hospitals

Clinics

Market segment by players, this report covers

Ipsen Pharma

Merck & Co., Inc.

Bristol-Myers Squibb Company

Eli Lilly

Roche

Novartis AG

Bayer AG

Celltrion Inc.

TAIHO PHARMACEUTICAL CO., LTD.

Jiangsu Hengrui Medicine Co., Ltd.

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Stomach Cancer and Gastric Cancer Drugs

1.2 Classification of Stomach Cancer and Gastric Cancer Drugs by Type

1.2.1 Overview: Global Stomach Cancer and Gastric Cancer Drugs Market Size by Type: 2020 Versus 2021 Versus 2026

1.2.2 Global Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Type in 2020

1.2.3 Programmed Cell Death Protein 1 (PD-1) Inhibitors

1.2.4 Human Epidermal Growth Factor Receptor (HER2) Antagonists

1.2.5 Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists

1.2.6 Others

1.3 Global Stomach Cancer and Gastric Cancer Drugs Market by Application

1.3.1 Overview: Global Stomach Cancer and Gastric Cancer Drugs Market Size by Application: 2020 Versus 2021 Versus 2026

1.3.2 Hospitals

1.3.3 Clinics

1.4 Global Stomach Cancer and Gastric Cancer Drugs Market Size & Forecast

1.5 Global Stomach Cancer and Gastric Cancer Drugs Market Size and Forecast by Region

1.5.1 Global Stomach Cancer and Gastric Cancer Drugs Market Size by Region: 2016 VS 2021 VS 2026

1.5.2 Global Stomach Cancer and Gastric Cancer Drugs Market Size by Region, (2016-2021)

1.5.3 North America Stomach Cancer and Gastric Cancer Drugs Market Size and Prospect (2016-2026)

1.5.4 Europe Stomach Cancer and Gastric Cancer Drugs Market Size and Prospect (2016-2026)

1.5.5 Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Market Size and Prospect (2016-2026)

1.5.6 South America Stomach Cancer and Gastric Cancer Drugs Market Size and Prospect (2016-2026)

1.5.7 Middle East and Africa Stomach Cancer and Gastric Cancer Drugs Market Size and Prospect (2016-2026)

1.6 Market Drivers, Restraints and Trends

1.6.1 Stomach Cancer and Gastric Cancer Drugs Market Drivers

1.6.2 Stomach Cancer and Gastric Cancer Drugs Market Restraints

1.6.3 Stomach Cancer and Gastric Cancer Drugs Trends Analysis

2 Company Profiles

2.1 Ipsen Pharma

2.1.1 Ipsen Pharma Details

2.1.2 Ipsen Pharma Major Business

2.1.3 Ipsen Pharma Stomach Cancer and Gastric Cancer Drugs Product and Solutions

2.1.4 Ipsen Pharma Stomach Cancer and Gastric Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.1.5 Ipsen Pharma Recent Developments and Future Plans

2.2 Merck & Co., Inc.

2.2.1 Merck & Co., Inc. Details

2.2.2 Merck & Co., Inc. Major Business

2.2.3 Merck & Co., Inc. Stomach Cancer and Gastric Cancer Drugs Product and Solutions

2.2.4 Merck & Co., Inc. Stomach Cancer and Gastric Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.2.5 Merck & Co., Inc. Recent Developments and Future Plans

2.3 Bristol-Myers Squibb Company

2.3.1 Bristol-Myers Squibb Company Details

2.3.2 Bristol-Myers Squibb Company Major Business

2.3.3 Bristol-Myers Squibb Company Stomach Cancer and Gastric Cancer Drugs Product and Solutions

2.3.4 Bristol-Myers Squibb Company Stomach Cancer and Gastric Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.3.5 Bristol-Myers Squibb Company Recent Developments and Future Plans

2.4 Eli Lilly

2.4.1 Eli Lilly Details

2.4.2 Eli Lilly Major Business

2.4.3 Eli Lilly Stomach Cancer and Gastric Cancer Drugs Product and Solutions

2.4.4 Eli Lilly Stomach Cancer and Gastric Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.4.5 Eli Lilly Recent Developments and Future Plans

2.5 Roche

2.5.1 Roche Details

2.5.2 Roche Major Business

2.5.3 Roche Stomach Cancer and Gastric Cancer Drugs Product and Solutions

2.5.4 Roche Stomach Cancer and Gastric Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.5.5 Roche Recent Developments and Future Plans

2.6 Novartis AG

2.6.1 Novartis AG Details

2.6.2 Novartis AG Major Business

2.6.3 Novartis AG Stomach Cancer and Gastric Cancer Drugs Product and Solutions

2.6.4 Novartis AG Stomach Cancer and Gastric Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.6.5 Novartis AG Recent Developments and Future Plans

2.7 Bayer AG

2.7.1 Bayer AG Details

2.7.2 Bayer AG Major Business

2.7.3 Bayer AG Stomach Cancer and Gastric Cancer Drugs Product and Solutions

2.7.4 Bayer AG Stomach Cancer and Gastric Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.7.5 Bayer AG Recent Developments and Future Plans

2.8 Celltrion Inc.

2.8.1 Celltrion Inc. Details

2.8.2 Celltrion Inc. Major Business

2.8.3 Celltrion Inc. Stomach Cancer and Gastric Cancer Drugs Product and Solutions

2.8.4 Celltrion Inc. Stomach Cancer and Gastric Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.8.5 Celltrion Inc. Recent Developments and Future Plans

2.9 TAIHO PHARMACEUTICAL CO., LTD.

2.9.1 TAIHO PHARMACEUTICAL CO., LTD. Details

2.9.2 TAIHO PHARMACEUTICAL CO., LTD. Major Business

2.9.3 TAIHO PHARMACEUTICAL CO., LTD. Stomach Cancer and Gastric Cancer Drugs Product and Solutions

2.9.4 TAIHO PHARMACEUTICAL CO., LTD. Stomach Cancer and Gastric Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.9.5 TAIHO PHARMACEUTICAL CO., LTD. Recent Developments and Future Plans

2.10 Jiangsu Hengrui Medicine Co., Ltd.

2.10.1 Jiangsu Hengrui Medicine Co., Ltd. Details

2.10.2 Jiangsu Hengrui Medicine Co., Ltd. Major Business

2.10.3 Jiangsu Hengrui Medicine Co., Ltd. Stomach Cancer and Gastric Cancer Drugs Product and Solutions

2.10.4 Jiangsu Hengrui Medicine Co., Ltd. Stomach Cancer and Gastric Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)

2.10.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Stomach Cancer and Gastric Cancer Drugs Revenue and Share by Players (2019-2021)

3.2 Market Concentration Rate

3.2.1 Top 3 Stomach Cancer and Gastric Cancer Drugs Players Market Share

3.2.2 Top 10 Stomach Cancer and Gastric Cancer Drugs Players Market Share

3.2.3 Market Competition Trend

3.3 Stomach Cancer and Gastric Cancer Drugs Players Head Office, Products and Services Provided

3.4 Mergers & Acquisitions

3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Stomach Cancer and Gastric Cancer Drugs Revenue and Market Share by Type (2016-2021)

4.2 Global Stomach Cancer and Gastric Cancer Drugs Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

5.1 Global Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Application (2016-2021)

5.2 Stomach Cancer and Gastric Cancer Drugs Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

6.1 North America Stomach Cancer and Gastric Cancer Drugs Revenue by Type (2016-2026)

6.2 North America Stomach Cancer and Gastric Cancer Drugs Revenue by Application (2016-2026)

6.3 North America Stomach Cancer and Gastric Cancer Drugs Market Size by Country

6.3.1 North America Stomach Cancer and Gastric Cancer Drugs Revenue by Country (2016-2026)

6.3.2 United States Stomach Cancer and Gastric Cancer Drugs Market Size and Forecast (2016-2026)

6.3.3 Canada Stomach Cancer and Gastric Cancer Drugs Market Size and Forecast (2016-2026)

6.3.4 Mexico Stomach Cancer and Gastric Cancer Drugs Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

7.1 Europe Stomach Cancer and Gastric Cancer Drugs Revenue by Type (2016-2026)

7.2 Europe Stomach Cancer and Gastric Cancer Drugs Revenue by Application (2016-2026)

7.3 Europe Stomach Cancer and Gastric Cancer Drugs Market Size by Country

7.3.1 Europe Stomach Cancer and Gastric Cancer Drugs Revenue by Country (2016-2026)

7.3.2 Germany Stomach Cancer and Gastric Cancer Drugs Market Size and Forecast (2016-2026)

7.3.3 France Stomach Cancer and Gastric Cancer Drugs Market Size and Forecast (2016-2026)

7.3.4 United Kingdom Stomach Cancer and Gastric Cancer Drugs Market Size and Forecast (2016-2026)

7.3.5 Russia Stomach Cancer and Gastric Cancer Drugs Market Size and Forecast (2016-2026)

7.3.6 Italy Stomach Cancer and Gastric Cancer Drugs Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Revenue by Type (2016-2026)

8.2 Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Revenue by Application (2016-2026)

8.3 Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Market Size by Region

8.3.1 Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Revenue by Region (2016-2026)

8.3.2 China Stomach Cancer and Gastric Cancer Drugs Market Size and Forecast (2016-2026)

8.3.3 Japan Stomach Cancer and Gastric Cancer Drugs Market Size and Forecast (2016-2026)

8.3.4 South Korea Stomach Cancer and Gastric Cancer Drugs Market Size and Forecast (2016-2026)

8.3.5 India Stomach Cancer and Gastric Cancer Drugs Market Size and Forecast (2016-2026)

8.3.6 Southeast Asia Stomach Cancer and Gastric Cancer Drugs Market Size and Forecast (2016-2026)

8.3.7 Australia Stomach Cancer and Gastric Cancer Drugs Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

9.1 South America Stomach Cancer and Gastric Cancer Drugs Revenue by Type (2016-2026)

9.2 South America Stomach Cancer and Gastric Cancer Drugs Revenue by Application (2016-2026)

9.3 South America Stomach Cancer and Gastric Cancer Drugs Market Size by Country

9.3.1 South America Stomach Cancer and Gastric Cancer Drugs Revenue by Country (2016-2026)

9.3.2 Brazil Stomach Cancer and Gastric Cancer Drugs Market Size and Forecast (2016-2026)

9.3.3 Argentina Stomach Cancer and Gastric Cancer Drugs Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Revenue by Type (2016-2026)

10.2 Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Revenue by Application (2016-2026)

10.3 Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Market Size by Country

10.3.1 Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Revenue by Country (2016-2026)

10.3.2 Turkey Stomach Cancer and Gastric Cancer Drugs Market Size and Forecast (2016-2026)

10.3.3 Saudi Arabia Stomach Cancer and Gastric Cancer Drugs Market Size and Forecast (2016-2026)

10.3.4 UAE Stomach Cancer and Gastric Cancer Drugs Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Stomach Cancer and Gastric Cancer Drugs Revenue by Type, (USD Million), 2020 VS 2021 VS 2026

Table 2. Global Stomach Cancer and Gastric Cancer Drugs Revenue by Application, (USD Million), 2020 VS 2021 VS 2026

Table 3. Global Market Stomach Cancer and Gastric Cancer Drugs Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)

Table 4. Global Stomach Cancer and Gastric Cancer Drugs Revenue (USD Million) by Region (2016-2021)

Table 5. Global Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Region (2021-2026)

Table 6. Ipsen Pharma Corporate Information, Head Office, and Major Competitors

Table 7. Ipsen Pharma Major Business

Table 8. Ipsen Pharma Stomach Cancer and Gastric Cancer Drugs Product and Solutions

Table 9. Ipsen Pharma Stomach Cancer and Gastric Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 10. Merck & Co., Inc. Corporate Information, Head Office, and Major Competitors

Table 11. Merck & Co., Inc. Major Business

Table 12. Merck & Co., Inc. Stomach Cancer and Gastric Cancer Drugs Product and Solutions

Table 13. Merck & Co., Inc. Stomach Cancer and Gastric Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 14. Bristol-Myers Squibb Company Corporate Information, Head Office, and Major Competitors

Table 15. Bristol-Myers Squibb Company Major Business

Table 16. Bristol-Myers Squibb Company Stomach Cancer and Gastric Cancer Drugs Product and Solutions

Table 17. Bristol-Myers Squibb Company Stomach Cancer and Gastric Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 18. Eli Lilly Corporate Information, Head Office, and Major Competitors

Table 19. Eli Lilly Major Business

Table 20. Eli Lilly Stomach Cancer and Gastric Cancer Drugs Product and Solutions

Table 21. Eli Lilly Stomach Cancer and Gastric Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 22. Roche Corporate Information, Head Office, and Major Competitors

Table 23. Roche Major Business

Table 24. Roche Stomach Cancer and Gastric Cancer Drugs Product and Solutions

Table 25. Roche Stomach Cancer and Gastric Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 26. Novartis AG Corporate Information, Head Office, and Major Competitors

Table 27. Novartis AG Major Business

Table 28. Novartis AG Stomach Cancer and Gastric Cancer Drugs Product and Solutions

Table 29. Novartis AG Stomach Cancer and Gastric Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 30. Bayer AG Corporate Information, Head Office, and Major Competitors

Table 31. Bayer AG Major Business

Table 32. Bayer AG Stomach Cancer and Gastric Cancer Drugs Product and Solutions

Table 33. Bayer AG Stomach Cancer and Gastric Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 34. Celltrion Inc. Corporate Information, Head Office, and Major Competitors

Table 35. Celltrion Inc. Major Business

Table 36. Celltrion Inc. Stomach Cancer and Gastric Cancer Drugs Product and Solutions

Table 37. Celltrion Inc. Stomach Cancer and Gastric Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 38. TAIHO PHARMACEUTICAL CO., LTD. Corporate Information, Head Office, and Major Competitors

Table 39. TAIHO PHARMACEUTICAL CO., LTD. Major Business

Table 40. TAIHO PHARMACEUTICAL CO., LTD. Stomach Cancer and Gastric Cancer Drugs Product and Solutions

Table 41. TAIHO PHARMACEUTICAL CO., LTD. Stomach Cancer and Gastric Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 42. Jiangsu Hengrui Medicine Co., Ltd. Corporate Information, Head Office, and Major Competitors

Table 43. Jiangsu Hengrui Medicine Co., Ltd. Major Business

Table 44. Jiangsu Hengrui Medicine Co., Ltd. Stomach Cancer and Gastric Cancer Drugs Product and Solutions

Table 45. Jiangsu Hengrui Medicine Co., Ltd. Stomach Cancer and Gastric Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 46. Global Stomach Cancer and Gastric Cancer Drugs Revenue (USD Million) by Players (2019-2021)

Table 47. Global Stomach Cancer and Gastric Cancer Drugs Revenue Share by Players (2019-2021)

Table 48. Breakdown of Stomach Cancer and Gastric Cancer Drugs by Company Type (Tier 1, Tier 2 and Tier 3)

Table 49. Stomach Cancer and Gastric Cancer Drugs Players Head Office, Products and Services Provided

Table 50. Stomach Cancer and Gastric Cancer Drugs Mergers & Acquisitions in the Past Five Years

Table 51. Stomach Cancer and Gastric Cancer Drugs New Entrants and Expansion Plans

Table 52. Global Stomach Cancer and Gastric Cancer Drugs Revenue (USD Million) by Type (2016-2021)

Table 53. Global Stomach Cancer and Gastric Cancer Drugs Revenue Share by Type (2016-2021)

Table 54. Global Stomach Cancer and Gastric Cancer Drugs Revenue Forecast by Type (2021-2026)

Table 55. Global Stomach Cancer and Gastric Cancer Drugs Revenue by Application (2016-2021)

Table 56. Global Stomach Cancer and Gastric Cancer Drugs Revenue Forecast by Application (2021-2026)

Table 57. North America Stomach Cancer and Gastric Cancer Drugs Revenue by Type (2016-2021) & (USD Million)

Table 58. North America Stomach Cancer and Gastric Cancer Drugs Revenue by Type (2021-2026) & (USD Million)

Table 59. North America Stomach Cancer and Gastric Cancer Drugs Revenue by Application (2016-2021) & (USD Million)

Table 60. North America Stomach Cancer and Gastric Cancer Drugs Revenue by Application (2021-2026) & (USD Million)

Table 61. North America Stomach Cancer and Gastric Cancer Drugs Revenue by Country (2016-2021) & (USD Million)

Table 62. North America Stomach Cancer and Gastric Cancer Drugs Revenue by Country (2021-2026) & (USD Million)

Table 63. Europe Stomach Cancer and Gastric Cancer Drugs Revenue by Type (2016-2021) & (USD Million)

Table 64. Europe Stomach Cancer and Gastric Cancer Drugs Revenue by Type (2021-2026) & (USD Million)

Table 65. Europe Stomach Cancer and Gastric Cancer Drugs Revenue by Application (2016-2021) & (USD Million)

Table 66. Europe Stomach Cancer and Gastric Cancer Drugs Revenue by Application (2021-2026) & (USD Million)

Table 67. Europe Stomach Cancer and Gastric Cancer Drugs Revenue by Country (2016-2021) & (USD Million)

Table 68. Europe Stomach Cancer and Gastric Cancer Drugs Revenue by Country (2021-2026) & (USD Million)

Table 69. Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Revenue by Type (2016-2021) & (USD Million)

Table 70. Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Revenue by Type (2021-2026) & (USD Million)

Table 71. Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Revenue by Application (2016-2021) & (USD Million)

Table 72. Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Revenue by Application (2021-2026) & (USD Million)

Table 73. Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Revenue by Region (2016-2021) & (USD Million)

Table 74. Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Revenue by Region (2021-2026) & (USD Million)

Table 75. South America Stomach Cancer and Gastric Cancer Drugs Revenue by Type (2016-2021) & (USD Million)

Table 76. South America Stomach Cancer and Gastric Cancer Drugs Revenue by Type (2021-2026) & (USD Million)

Table 77. South America Stomach Cancer and Gastric Cancer Drugs Revenue by Application (2016-2021) & (USD Million)

Table 78. South America Stomach Cancer and Gastric Cancer Drugs Revenue by Application (2021-2026) & (USD Million)

Table 79. South America Stomach Cancer and Gastric Cancer Drugs Revenue by Country (2016-2021) & (USD Million)

Table 80. South America Stomach Cancer and Gastric Cancer Drugs Revenue by Country (2021-2026) & (USD Million)

Table 81. Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Revenue by Type (2016-2021) & (USD Million)

Table 82. Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Revenue by Type (2021-2026) & (USD Million)

Table 83. Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Revenue by Application (2016-2021) & (USD Million)

Table 84. Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Revenue by Application (2021-2026) & (USD Million)

Table 85. Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Revenue by Country (2016-2021) & (USD Million)

Table 86. Middle East & Africa Stomach Cancer and Gastric Cancer Drugs Revenue by Country (2021-2026) & (USD Million)

List of Figures

Figure 1. Stomach Cancer and Gastric Cancer Drugs Picture

Figure 2. Global Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Type in 2020

Figure 3. Programmed Cell Death Protein 1 (PD-1) Inhibitors

Figure 4. Human Epidermal Growth Factor Receptor (HER2) Antagonists

Figure 5. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists

Figure 6. Others

Figure 7. Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Application in 2020

Figure 8. Hospitals Picture

Figure 9. Clinics Picture

Figure 10. Global Stomach Cancer and Gastric Cancer Drugs Revenue, (USD Million): 2020 VS 2021 VS 2026

Figure 11. Global Stomach Cancer and Gastric Cancer Drugs Revenue and Forecast (2016-2026) & (USD Million)

Figure 12. Global Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Region (2016-2026)

Figure 13. Global Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Region in 2020

Figure 14. North America Stomach Cancer and Gastric Cancer Drugs Revenue (USD Million) and Growth Rate (2016-2026)

Figure 15. Europe Stomach Cancer and Gastric Cancer Drugs Revenue (USD Million) and Growth Rate (2016-2026)

Figure 16. Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Revenue (USD Million) and Growth Rate (2016-2026)

Figure 17. South America Stomach Cancer and Gastric Cancer Drugs Revenue (USD Million) and Growth Rate (2016-2026)

Figure 18. Middle East and Africa Stomach Cancer and Gastric Cancer Drugs Revenue (USD Million) and Growth Rate (2016-2026)

Figure 19. Stomach Cancer and Gastric Cancer Drugs Market Drivers

Figure 20. Stomach Cancer and Gastric Cancer Drugs Market Restraints

Figure 21. Stomach Cancer and Gastric Cancer Drugs Market Trends

Figure 22. Ipsen Pharma Recent Developments and Future Plans

Figure 23. Merck & Co., Inc. Recent Developments and Future Plans

Figure 24. Bristol-Myers Squibb Company Recent Developments and Future Plans

Figure 25. Eli Lilly Recent Developments and Future Plans

Figure 26. Roche Recent Developments and Future Plans

Figure 27. Novartis AG Recent Developments and Future Plans

Figure 28. Bayer AG Recent Developments and Future Plans

Figure 29. Celltrion Inc. Recent Developments and Future Plans

Figure 30. TAIHO PHARMACEUTICAL CO., LTD. Recent Developments and Future Plans

Figure 31. Jiangsu Hengrui Medicine Co., Ltd. Recent Developments and Future Plans

Figure 32. Global Stomach Cancer and Gastric Cancer Drugs Revenue Share by Players in 2020

Figure 33. Stomach Cancer and Gastric Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 34. Global Top 3 Players Stomach Cancer and Gastric Cancer Drugs Revenue Market Share in 2020

Figure 35. Global Top 10 Players Stomach Cancer and Gastric Cancer Drugs Revenue Market Share in 2020

Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)

Figure 37. Global Stomach Cancer and Gastric Cancer Drugs Revenue Share by Type in 2020

Figure 38. Global Stomach Cancer and Gastric Cancer Drugs Market Share Forecast by Type (2021-2026)

Figure 39. Global Stomach Cancer and Gastric Cancer Drugs Revenue Share by Application in 2020

Figure 40. Global Stomach Cancer and Gastric Cancer Drugs Market Share Forecast by Application (2021-2026)

Figure 41. North America Stomach Cancer and Gastric Cancer Drugs Sales Market Share by Type (2016-2026)

Figure 42. North America Stomach Cancer and Gastric Cancer Drugs Sales Market Share by Application (2016-2026)

Figure 43. North America Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Country (2016-2026)

Figure 44. United States Stomach Cancer and Gastric Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 45. Canada Stomach Cancer and Gastric Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 46. Mexico Stomach Cancer and Gastric Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 47. Europe Stomach Cancer and Gastric Cancer Drugs Sales Market Share by Type (2016-2026)

Figure 48. Europe Stomach Cancer and Gastric Cancer Drugs Sales Market Share by Application (2016-2026)

Figure 49. Europe Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Country (2016-2026)

Figure 50. Germany Stomach Cancer and Gastric Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 51. France Stomach Cancer and Gastric Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 52. United Kingdom Stomach Cancer and Gastric Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 53. Russia Stomach Cancer and Gastric Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 54. Italy Stomach Cancer and Gastric Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 55. Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Sales Market Share by Type (2016-2026)

Figure 56. Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Sales Market Share by Application (2016-2026)

Figure 57. Asia-Pacific Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Region (2016-2026)

Figure 58. China Stomach Cancer and Gastric Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 59. Japan Stomach Cancer and Gastric Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 60. South Korea Stomach Cancer and Gastric Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 61. India Stomach Cancer and Gastric Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 62. Southeast Asia Stomach Cancer and Gastric Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 63. Australia Stomach Cancer and Gastric Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 64. South America Stomach Cancer and Gastric Cancer Drugs Sales Market Share by Type (2016-2026)

Figure 65. South America Stomach Cancer and Gastric Cancer Drugs Sales Market Share by Application (2016-2026)

Figure 66. South America Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Country (2016-2026)

Figure 67. Brazil Stomach Cancer and Gastric Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 68. Argentina Stomach Cancer and Gastric Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 69. Middle East and Africa Stomach Cancer and Gastric Cancer Drugs Sales Market Share by Type (2016-2026)

Figure 70. Middle East and Africa Stomach Cancer and Gastric Cancer Drugs Sales Market Share by Application (2016-2026)

Figure 71. Middle East and Africa Stomach Cancer and Gastric Cancer Drugs Revenue Market Share by Country (2016-2026)

Figure 72. Turkey Stomach Cancer and Gastric Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 73. Saudi Arabia Stomach Cancer and Gastric Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 74. UAE Stomach Cancer and Gastric Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 75. Methodology

Figure 76. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz